A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3

PHASE3CompletedINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 2000

Conditions
HIV Infections
Interventions
DRUG

Aldesleukin

Trial Locations (15)

10037

Harlem AIDS Treatment Grp / Harlem Hosp Ctr, New York

19107

Philadelphia FIGHT, Philadelphia

20422

Washington Reg AIDS Prog / Dept of Infect Dis, Washington D.C.

23298

Richmond AIDS Consortium / Div of Infect Diseases, Richmond

30308

AIDS Research Consortium of Atlanta, Atlanta

48201

Wayne State Univ - WSU/DMC / Univ Hlth Ctr, Detroit

48202

Henry Ford Hosp, Detroit

60657

AIDS Research Alliance - Chicago, Chicago

70112

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans

80204

Denver CPCRA / Denver Public Hlth, Denver

87131

Partners in Research / New Mexico, Albuquerque

94110

Community Consortium / UCSF, San Francisco

97210

The Research and Education Group, Portland

08103

Southern New Jersey AIDS Clinical Trials, Camden

07103

North Jersey Community Research Initiative, Newark

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH